Share of total health spending, by percentile

Nature of the Spending Distribution

• Many see the “1% account for 24% of spending / 5% for ~50%” as a typical Pareto-like pattern and exactly what you’d expect from insurance.
• Analogies are made to car or fire insurance: a small minority have very expensive events, most people have little or no claims.
• Several note that a large share of individual spending often occurs in a single acute episode or in the last year(s) of life.

Interpretation and Framing Concerns

• Multiple commenters question whether the data are per-year or lifetime; per-year stats can be misleading since people move in and out of the top percentiles.
• Some argue the headline “1% are responsible…” sounds accusatory and encourages hostility toward high-cost patients.
• Others stress that such analysis is standard actuarial work, but framing matters for public perception.

Drug Prices and Insurance Mechanics

• Numerous anecdotes describe extremely costly biologics and specialty drugs (e.g., $25k per mL injections, six-figure annual list prices) with tiny copays but very high insurance premiums.
• Discussion of lifetime benefit caps pre-ACA and people being driven to medical tourism after hitting limits.
• Several commenters highlight pharmacy benefit managers, manufacturer discount programs, and complex vertical integration (insurer–PBM–provider) as major cost drivers and sources of opaque “shenanigans.”
• Debate over whether pharma spends more on marketing than R&D, with conflicting links and arguments about accounting categories.

System Design, Incentives, and Cost Control

• Hidden costs via employer-sponsored premiums are seen as a barrier to reform.
• Some argue the real issue is not the skewed distribution but uncontrolled absolute prices, especially for insulin and other long‑established drugs.
• Comparisons to other countries emphasize stronger centralized price negotiation (“take the 90%-as-good option for 10% of the cost”) as a missing U.S. tool.
• Example from an emergency department: proactively funding routine care and transport for a small group of uninsured high‑utilizers dramatically reduced overall costs.

Ethical and Policy Debates

• Tension between holding individuals responsible for lifestyle-related illness versus recognizing genetic and random factors; one country’s model (genetic fully covered, lifestyle partly taxed) is mentioned.
• Several push back against any eugenic or “sacrifice the 1%” implications, insisting that the point of insurance is precisely to cover those unlucky few.
• Some suggest separating chronic vs acute spending and considering expected quality years of life as better policy metrics.